OR WAIT null SECS
Valitacell and Solentim, have announced a collaboration aimed at the acceleration of discovery and development of biologic drugs and advanced cell therapies.
Biotech company, Valitacell, and cell-line development instrumentation company, Solentim, have announced a collaboration aimed at the acceleration of discovery and development of biologic drugs and advanced cell therapies.
The companies are targeting the creation of an automated platform that synergizes precise cell manipulations, attribute-rich profiling of clones, and earlier decision making. This platform will be created through the use of Valitacell’s in-line analytical profiling technologies and data-driven/machine learning approach along with Solentim’s image-driven liquid handling and cell measurement technology, Valitacell announced in a Feb. 21, 2019 press release.
“This collaboration combines our expertise in both biotherapeutics and emergent cellular therapy, and will optimize the process of drug discovery,” said Terry McWade, CEO of Valitacell. “We look forward to working in partnership with Solentim as we continue to discover and develop life-saving medicines that improve patients’ lives.”
Ian Taylor, chief commercial officer of Solentim, added: “We are delighted to be collaborating with Valitacell-this combination of technologies will provide a further component to our unique integrated solution for accelerating stable cell line development workflows. It will provide significant benefits for richer clone information and earlier decision-making on the best candidates to progress.”